Ask AI
Selecting Patients for Bridging Therapy in RR MM

CE / CME

Identifying Patients Likely to Benefit From Bridging Therapy Before CAR T-Cell Infusion  in R/R MM 

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 29, 2025

Expiration: June 28, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Krina K. Patel, MD, MSc, outlines the rationale for the broad use of bridging therapy prior to CAR T-cell infusion, highlighting clinical data that support its role in improving long-term CAR T-cell therapy outcomes. Dr Patel reviews real-world patient cases to illustrate her decision-making process, including when bridging therapy is necessary and which patient and disease characteristics should be considered. The module concludes with practical clinical pearls for selecting bridging therapy, as well as a discussion of ongoing challenges and unanswered questions in this evolving area.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

Which factor has been shown to be most associated with improved efficacy and reduced toxicity in patients receiving CAR T-cell therapy (eg, idecabtagene vicleucel [ide-cel] or ciltacabtagene autoleucel [cilta-cel]) for relapsed/refractory (R/R) multiple myeloma (MM)?

How many people with MM do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting: